Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IV, Prospective, Single-Arm, Open-Label Study to Measure Outcomes in Patients With Pulmonary Arterial Hypertension Not on Active Treatment

Next Previous
X
Search
Trial Profile

A Phase IV, Prospective, Single-Arm, Open-Label Study to Measure Outcomes in Patients With Pulmonary Arterial Hypertension Not on Active Treatment

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms MOTION
  • Sponsors Bayer

    • Most Recent Events

    • 13 Nov 2023 Results of pooled post hoc analysis (n=741 from studies PATENT-1, PATENT PLUS, RESPITE, MOTION, REPLACE) assessing the impact of riociguat in patients with PAH and comorbidities presented at the American Heart Association Scientific Sessions 2023
    • 24 May 2017 Primary endpoint has been met (Living with Pulmonary Hypertension questionnaire (LPH)), according to results presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top